Brief: Kyowa Kirin Provides Update On Application For Marketing Authorisation Of Istradefylline In Europe For The Treatment Of ‘Off’ Episodes In People Living With Parkinson’S
23/07/2021 16:38
July 23 (Reuters) - Kyowa Kirin Co Ltd 4151.T :
* KYOWA KIRIN PROVIDES UPDATE ON APPLICATION FOR MARKETING
AUTHORISATION OF ISTRADEFYLLINE IN EUROPE FOR THE TREATMENT OF
‘OFF’ EPISODES IN PEOPLE LIVING WITH PARKINSON’S
* KYOWA KIRIN CO LTD - EMA COMMITTEE FOR MEDICINAL PRODUCTS
FOR
HUMAN USE ISSUED NEGATIVE OPINION FOR ISTRADEFYLLINE AS AN
ADD-ON TREATMENT TO LEVODOPA
* KYOWA KIRIN CO LTD - CURRENTLY REVIEWING OPTIONS
AVAILABLE,
WHICH MAY INCLUDE RE-EXAMINATION
Source text for Eikon: ID:nBw3b1pX9a
Further company coverage: 4151.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia